Moreover, reduced expression of MTA3 in tumor specimens has been associated with poor survival and therefore the expression of MTA3 has been suggested as an independent predictor of patient prognosis in uterine non-endometrioid carcinomas, gastroesophageal junction adenocarcinoma, glioma, and colorectal cancer (27, 28, 31, 32). This evidence concerns the gene MTA3 and glioma.